Based on the finding that 15–20% of all cancer cases are associated with pre-existing inflammation and there is a strong link between intestinal inflammation and colorectal cancer [2,3], we sought to elucidate whether mice with an intestinal deletion of Usp22 were more prone to developing inflammation-associated CRC. This evidence concerns the gene USP22 and cancer.